{
    "ticker": "MEIP",
    "name": "Mei Pharma, Inc.",
    "description": "Mei Pharma, Inc. is a clinical-stage pharmaceutical company focused on advancing the development of novel oncology therapies. Founded in 2000 and based in San Diego, California, Mei Pharma is dedicated to improving the lives of patients with cancer through innovative drug development. The company's lead product candidates include Pracinostat, an oral histone deacetylase (HDAC) inhibitor, which is being evaluated in combination with standard-of-care therapies for patients with hematologic malignancies. Additionally, Mei Pharma\u2019s pipeline includes several other promising compounds aimed at treating various types of cancer, showcasing their commitment to addressing unmet medical needs in oncology. With a robust clinical development strategy, Mei Pharma aims to bring breakthrough therapies to market that enhance the efficacy of existing cancer treatments while minimizing side effects. The company's mission is rooted in the belief that every cancer patient deserves access to effective and safe treatment options, and it continues to collaborate with leading research institutions and healthcare professionals to propel its innovative therapies forward.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2000",
    "website": "https://www.meipharma.com",
    "ceo": "David A. Urso",
    "social_media": {
        "twitter": "https://twitter.com/MeiPharma",
        "linkedin": "https://www.linkedin.com/company/meipharma"
    },
    "investor_relations": "https://investors.meipharma.com",
    "key_executives": [
        {
            "name": "David A. Urso",
            "position": "CEO"
        },
        {
            "name": "Mark R. Hager",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "Pracinostat",
                "ME-401",
                "ME-344"
            ]
        }
    ],
    "seo": {
        "meta_title": "Mei Pharma, Inc. | Innovative Oncology Therapies",
        "meta_description": "Explore Mei Pharma, Inc., a clinical-stage pharmaceutical company focused on developing novel oncology therapies to improve cancer treatment outcomes.",
        "keywords": [
            "Mei Pharma",
            "Oncology",
            "Pharmaceuticals",
            "Cancer Treatment",
            "Pracinostat"
        ]
    },
    "faq": [
        {
            "question": "What is Mei Pharma known for?",
            "answer": "Mei Pharma is known for its development of innovative oncology therapies, particularly its lead product candidate Pracinostat."
        },
        {
            "question": "Who is the CEO of Mei Pharma?",
            "answer": "David A. Urso is the CEO of Mei Pharma, Inc."
        },
        {
            "question": "Where is Mei Pharma headquartered?",
            "answer": "Mei Pharma is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are Mei Pharma's main products?",
            "answer": "Mei Pharma's main products include Pracinostat, ME-401, and ME-344."
        },
        {
            "question": "When was Mei Pharma founded?",
            "answer": "Mei Pharma was founded in 2000."
        }
    ],
    "competitors": [
        "CLVS",
        "TGTX",
        "PBYI",
        "IMMU"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}